Drug intelligence / Profile preview

FL-115

Development stage
Phase 2
Lead developer
Forlong Biotechnology
Modality
Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

FL-115 is a novel, long-acting interleukin 15 (IL-15) agonist designed as a fusion protein composed of a mutated form of IL-15 (N72D mutation) and the IL-15 receptor alpha subunit fused to an Fc domain. This design aims to overcome the short half-life of recombinant IL-15 and enhance tumor penetration due to its small molecular weight. The drug acts by targeting the interleukin 15 receptor subunit alpha (IL15RA), stimulating immune responses against tumors. It is administered intravenously and is currently in Phase I clinical trials for advanced solid tumors, including non-small cell lung cancer and non-muscle invasive bladder cancer. FL-115 is being developed using F-body technology by Suzhou Forlong Biotechnology[1][2][3][4].

Other names
IL-15(N72D)/IL-15Ralpha-sFc fusion protein complex
02

Targets

IL15RA (Interleukin-15 receptor subunit alpha)

Beyond the preview

Go deeper on FL-115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FL-115.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call